Navigation Links
Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
Date:6/19/2008

PITTSBURGH, June 19 /PRNewswire/ -- Cohera Medical Inc. today announced that data published in the July issue of Plastic and Reconstructive Surgery show the company's surgical adhesive, TissuGlu, was effective in preventing the formation of seroma in an animal abdominoplasty model.

Summarized in a paper titled "Lysine-Derived Urethane Surgical Adhesive Prevents Seroma Formation in a Canine Abdominoplasty Model," (Plast. Reconstr. Surg. 2008; Vol. 122, Issue 1: 95-102) the results demonstrated that TissuGlu successfully prevented the formation of seroma in a novel large-animal model designed to evaluate seroma formation. While the control side in all seven animals used in the study demonstrated large, clinically significant seromas, the side treated with TissuGlu showed little or no evidence of fluid accumulation. In addition, histologic analysis of tissue samples from the animals showed no signs of inflammation or foreign body reaction associated with the adhesive.

"I am impressed with the experimental data that demonstrate a clear ability of the adhesive to control seroma formation in this animal model," said J. Peter Rubin, M.D., founder and director of the Life After Weight Loss surgical body contouring program at the University of Pittsburgh and the lead author of the paper. "This adhesive shows strong potential for widespread applications in many surgical specialties."

Surgeons have expressed a strong need for a product that adheres tissue flaps to help prevent the fluid accumulation that occurs between tissue layers after surgery. Surgical adhesives available today fall into two categories: "superglue"-type products that are strong but cannot be used inside the body because they break down into toxic byproducts and "fibrin sealant" products that are biocompatible but create a weak bond and are expensive and difficult to prepare during surgery.

"Seromas have been a major problem for post-surgical patients," said Susan E. Downey, M.D., a board-certified plastic surgeon at the Pacific SurgiCenter in Santa Monica, Calif. "This study demonstrates a great animal model and the efficacious use of an adhesive to address this difficult problem."

"The results illustrate the potential efficacy of TissuGlu and helps support the movement of TissuGlu into human clinical studies, which we expect to initiate next year," said Patrick Daly, president and CEO of Cohera Medical. "Our goal is to introduce to surgeons a tissue adhesive that encompasses the desired strong and effective bonding properties in a safe, resorbable and easy-to-use formulation."

Seroma formation is a frequent complication of plastic surgery procedures such as abdominoplasty, with complication rates ranging from 15 percent to 52 percent. In 2007, approximately 148,000 abdominoplasty, or "tummy tuck," procedures were performed in the United States, according to the American Society of Plastic Surgeons.

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the US or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Long-term safety data on Lialda published in leading GI journal
2. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
3. New Regulations for Hospice Provision Published by CMS
4. First Comprehensive Reference on Evidence-Based Design Published
5. Premier issue of Environmental Justice just published
6. Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
7. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
8. Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
9. 20th Edition of the Encyclopedia of Social Work Published
10. Clinical guidelines for the manual titration of PAP in OSA patients published in JCSM
11. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Revolution for Truth has organized the ... parental rights and civil liberties, and to restore transparency within government agencies responsible ... with a press conference taking place Friday morning calling on President Trump to ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
(Date:3/28/2017)... Pittsburgh, PA (PRWEB) , ... March 28, 2017 ... ... built for and by physicians, announced today the launch of a free, public-facing ... The Via Cost Analyzer (VCA) was developed to provide comparative information to patients, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , United Kingdom and  BOSTON , March ... provider Linguamatics today announced a partnership ... . The agreement allows pharmaceutical companies to extract ... I2E text mining technology. ... 18 of the top 20 global pharmaceutical companies. ...
(Date:3/28/2017)... Calif. , March 28, 2017  AcelRx ... focused on the development and commercialization of innovative ... announced that the European Medicines Agency (EMA) has ... tablet, 30 mcg) Marketing Authorisation Application (MAA) has ... the MAA is underway. The MAA for ARX-04 ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology: